Figure 1.
Colposcopic image of cervix with female genital schistosomiasis.
The image shows sandy patches appearing as grains (arrows point to some examples) and contact bleeding.
Figure 2.
Flowchart showing the inclusion of study participants (FGS = female genital schistosomiasis, CVL = cervicovaginal lavage).
Figure 3.
Figures showing the gating strategy for A) CD3+ B) CD3−CD56+ C) CD3+CD4+ and CD3+CD8+ and D) CD3−CD56−CD14+.
Table 1.
Characteristics of study participants by female genital schistosomiasis (FGS) status.
Figure 4.
Figures comparing the FGS positive (genital sandy patches) and negative (no genital sandy patches, negative Schistosoma PCR in cervicovaginal lavage/urine and negative urine microscopy for ova). Figures show blood (A–B) and cervical samples (C–D).
Figure 5.
Effect of praziquantel treatment.
Figures comparing FGS positive individuals in blood (A–B) and cervical samples (C–D) before and after praziquantel (40 mg/kg) treatment.